Publique un comentario 
Descargar PDF
Osteonecrosis mandibular: hallazgos clÃnicos e imagenológicos en un paciente tratado con denosumab
Resumen
Introducción: La administración de bifosfonatos y medicamentos antiangiogénicos en pacientes con cáncer es un esquema terapéutico usual en oncologÃa. Existen reportes de osteonecrosis de los maxilares en pacientes sometidos a este esquema de tratamiento, luego de realizar un procedimiento dental invasivo.
Objetivo: A partir de las caracterÃsticas clÃnicas e imagenológicas de la patologÃa, ilustrar al odontólogo sobre los medicamentos para el tratamiento del cáncer, susceptibles de generar osteonecrosis de los maxilares.
Presentación de caso: Paciente masculino de 89 años, con cáncer de próstata tratado con denosumab, que desarrolló osteonecrosis del maxilar inferior posterior a una extracción dental. Es de vital importancia que el odontólogo identifique los medicamentos, factores de riesgo y las medidas para minimizar el riesgo de osteonecrosis de los maxilares en pacientes susceptibles.
Â
Palabras clave
Referencias
Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115-7. DOI: 10.1016/s0278-2391(03)00720-1
Svejda B, Muschitz C, Gruber R, Brandtner C, Svejda C, Gasser RW, et al. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)]. Wien Med Wochenschr. 2016;166(1-2):68-74. DOI:10.1007/s10354-016-0437-2
Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22(10):1479-91. DOI:10.1359/jbmr.0707onj
Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw-2014 Update. J Oral Maxillofac Surg; 2014 [Acceso: 30/07/2020];72(10):1938-56. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0278239114004637
Fassio A, Bertoldo F, Idolazzi L, Viapiana O, Rossini M, Gatti D. Drug-induced osteonecrosis of the jaw: the state of the art. Reumatismo; 2017 [Acceso: 30/07/2020];69(1):9. Disponible en: http://www.reumatismo.org/index.php/reuma/article/view/983
Khan AA, Morrison A, Kendler DL, Rizzoli R, Hanley DA, Felsenberg D, et al. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ. J Clin Densitom; 2017 [Acceso: 30/07/2020];20(1):8-24. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S1094695016301962
for the MASCC Bone Study Group, Nicolatou-Galitis O, Kouri M, Papadopoulou E, Vardas E, Galiti D, et al. Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review. Support Care Cancer; 2019 [Acceso: 30/07/2020];27(2):383-94. Disponible en: http://link.springer.com/10.1007/s00520-018-4501-x
Koth VS, Figueiredo MA, Salum FG, Cherubini K. Bisphosphonate-related osteonecrosis of the jaw: from the sine qua non condition of bone exposure to a non-exposed BRONJ entity. Dentomaxillofac Radiol; 2016 [Acceso: 30/07/2020];45(7):20160049. Disponible en: http://www.birpublications.org/doi/10.1259/dmfr.20160049
Lorenzo-Pouso AI, Pérez-Sayáns M, Chamorro-Petronacci C, Gándara-Vila P, López-Jornet P, Carballo J, et al. Association between periodontitis and medication-related osteonecrosis of the jaw: A systematic review and meta-analysis. J Oral Pathol Med. 2020;49(3):190-200.
Rodriguez-Lozano F, Oñate-Sanchez R. Treatment of osteonecrosis of the jaw related to bisphosphonates and other antiresorptive agents. Med Oral; 2016 [Acceso: 30/07/2020];0-0. Disponible en: http://www.medicinaoral.com/medoralfree01/aop/20980.pdf
Sartori P, Rajcovich G, Taborda N, Daza MC, Nally C. Osteonecrosis del maxilar inferior por bifosfonatos. Presentación de caso. Rev argent radiol. 16/12/2014;66.
Moreno-Sánchez M, Monje Gil F, González-GarcÃa R, Manzano Solo de ZaldÃvar D. Bifosfonatos e implantes dentales, ¿son incompatibles? Revisión de la literatura. Rev Esp Cir Oral Maxilofac; 2016 [Acceso: 30/07/202038(3):128-35. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S1130055814001294
Diaz-Reverand SA, Naval-GÃaz L, Muñoz-Guerra MF, Sastre-Pérez J, RodrÃguez-Campo FJ, Gil-Diez JL, et al. Manejo de la osteonecrosis maxilar asociada al uso de medicamentos en virtud de su estadio clÃnico: análisis de 19 casos. Rev Esp Cir Oral Maxilofac; 2018 [Acceso: 30/07/2020];40(3):104-11. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_abstract&pid=S1130-05582018000300104&lng=es&nrm=iso&tlng=es
Greenspan SL, Perera S, Ferchak MA, Nace DA, Resnick NM. Efficacy and Safety of Single-Dose Zoledronic Acid for Osteoporosis in Frail Elderly Women: A Randomized Clinical Trial. JAMA Intern Med; 2015 [Acceso: 30/07/2020];175(6):913. Disponible en: http://archinte.jamanetwork.com/article.aspx?doi=10.1001/jamainternmed.2015.0747
Loyson T, Van Cann T, Schöffski P, Clement PM, Bechter O, Spriet I, et al. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab. Acta Clin Belg; 2018 [Acceso: 30/07/2020];73(2):100-9. Disponible en: https://www.tandfonline.com/doi/full/10.1080/17843286.2017.1348001
Shibahara T. Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): A Twist of Fate in the Bone. Tohoku J Exp Med; 2019 [Acceso: 30/07/2020];247(2):75-86. Disponible en: https://www.jstage.jst.go.jp/article/tjem/247/2/247_75/_article
Grey A, Bolland MJ, Horne A, Wattie D, House M, Gamble G, et al. Five years of anti-resorptive activity after a single dose of zoledronate-Results from a randomized double-blind placebo-controlled trial. Bone; 2012 [Acceso: 30/07/2020];50(6):1389-93. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S875632821200734X
Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol; 2012 [Acceso: 30/07/2020];23(5):1341-7. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0923753419346952
Mozzati M, Arata V, Gallesio G. Tooth extraction in patients on zoledronic acid therapy. Oral Oncol; 2012 [Acceso: 30/07/2020];48(9):817-21. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S1368837512000978
Eleutherakis-Papaiakovou E, Bamias A. Antiresorptive treatment-associated ONJ. Eur J Cancer Care; 2017 [Acceso: 30/07/2020];26(6):e12787. Disponible en: http://doi.wiley.com/10.1111/ecc.12787
Yamashita J, McCauley LK. Antiresorptives and Osteonecrosis of the Jaw. J. Evid Based Dent Pract; 2012 [Acceso: 30/07/2020];12(3):233-47. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S1532338212700465
Lo JC, O’Ryan FS, Gordon NP, Yang J, Hui RL, Martin D, et al. Prevalence of Osteonecrosis of the Jaw in Patients With Oral Bisphosphonate Exposure. J Oral Maxillofac Surg; 2010 [Acceso: 30/07/2020];68(2):243-53. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0278239109004418
Guarneri V, Miles D, Robert N, Diéras V, Glaspy J, Smith I, et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat; 2010 [Acceso: 30/07/2020];122(1):181-8. Disponible en: http://link.springer.com/10.1007/s10549-010-0866-3
Naylor KE, Bradburn M, Paggiosi MA, Gossiel F, Peel NFA, McCloskey EV, et al. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density. Osteoporos Int; 2018 [Acceso: 30/07/2020];29(6):1407-17. Disponible en: http://link.springer.com/10.1007/s00198-018-4460-6
McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, et al. Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug Holiday. Am J Med; 2013 [Acceso: 30/07/2020];126(1):13-20. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0002934312005876
McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, et al. Opposite Bone Remodeling Effects of Teriparatide and Alendronate in Increasing Bone Mass. Arch Intern Med; 2005 [Acceso: 30/07/2020];165(15):1762. Disponible en: http://archinte.jamanetwork.com/article.aspx?doi=10.1001/archinte.165.15.1762
Baba A, Ojiri H, Goto TK, Ikeda K, Yamauchi H, Ogino N, et al. Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (4), CT and MR imaging findings of antiresorptive agent-related osteonecrosis of the jaws/medication-related osteonecrosis of the jaw (secondary publication). Jpn Dent Sci Rev; 2019 [Acceso: 30/07/2020];55(1):58-64. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S1882761618300929
Baba A, Goto TK, Ojiri H, Takagiwa M, Hiraga C, Okamura M, et al. CT Imaging Features of Antiresorptive agent-Related Osteonecrosis of the Jaw/ Medication-Related Osteonecrosis of the Jaws. Dentomaxillofac Radiol; 2018 [Acceso: 30/07/2020];20170323. Disponible en: http://www.birpublications.org/doi/10.1259/dmfr.20170323
Kakehashi H, Ando T, Minamizato T, Nakatani Y, Kawasaki T, Ikeda H, et al. Administration of teriparatide improves the symptoms of advanced bisphosphonate-related osteonecrosis of the jaw: preliminary findings. Int J Oral Maxillofac Surg; 2015 [Acceso: 30/07/2020];44(12):1558-64. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0901502715012011
Kagami H, Inoue M, Kobayashi A, Taguchi A, Li X, Yoshizawa M. Issues with the surgical treatment of antiresorptive agent-related osteonecrosis of the jaws. Oral Dis; 2018 [Acceso: 30/07/2020];24(1-2):52-6. Disponible en: http://doi.wiley.com/10.1111/odi.12783
Eguchi T, Kanai I, Basugi A, Miyata Y, Inoue M, Hamada Y. The assessment of surgical and non-surgical treatment of stage II medication-related osteonecrosis of the jaw. Med Oral; 2017 [Acceso: 30/07/2020];0-0. Disponible en: http://www.medicinaoral.com/medoralfree01/aop/22013.pdf
